Octreotide LAR as Maintenance Treatment for Patients With NEC
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This is phase II study on the efficacy of octreotide lar as maintenance treatment after
first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic
or esophageal neuroendocrine carcinomas.